CEO received an award of 33K RMD derivative securities | OQRO Insider trades- Derivative units · @ $250.52
Why it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Nov 24, 2025
- Reporting period
- Not applicable
- Filed with the SEC
- Nov 27, 2025
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0000943819-25-000183
- Filed / recorded
Added to OQROOct 2, 2026, 12:28 PM UTC Data qualityVerified: identifiers matched exactly Reporting personMichael J. Farrell RelationshipDirector, Officer Officer titleChairman and CEO SecurityResMed Common Stock Options TableDerivative (Table II) Transaction dateNov 24, 2025 Acquired / disposedAcquired (A) Footnotes from the filing
- Represents the date on which options first become exercisable. The options vest in three equal annual installments commencing on November 11, 2026.
Around the same time
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$1.25M of ResMed|
Scheduled in advanceDerivative exercise or conversion — not an open-market buy.